Nextplat Corp (NXPL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Nextplat Corp for the period ended June 30, 2025. Nextplat operates two primary segments: e-Commerce Operations (satellite communication services and equipment sales via global platforms) and Healthcare Operations (pharmacy services, 340B contract services, and data management). The company is a smaller reporting company listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Net Revenue | $13,240 | $16,989 | $27,765 | $34,482 |
| Gross Profit | $2,883 | $5,858 | $6,346 | $10,720 |
| Gross Margin | 21.8% | 34.5% | 22.9% | 31.1% |
| Net Loss (Attributable to Nextplat) | $(1,789) | $(5,311) | $(3,132) | $(6,791) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.28) | $(0.12) | $(0.36) |
| Cash and Equivalents | $16,635 | $24,877 | $16,635 | $24,877 |
| Total Debt (Notes Payable) | $1,156 | $1,412 | $1,156 | $1,412 |
| Working Capital | $20,647 | $23,270 | $20,647 | $23,270 |
Note: Working Capital calculated as Total Current Assets ($26,855) minus Total Current Liabilities ($6,208).
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 22% in Q2 2025 compared to Q2 2024. This was driven by a 22% drop in Healthcare prescription revenue and a 68% drop in 340B contract revenue, partially offset by a 17% increase in e-Commerce revenue.
- Margin Compression: Gross margins contracted significantly from 34.5% to 21.8% in Q2. Healthcare margins fell due to lower prescription volumes and reimbursement rate adjustments. e-Commerce margins declined due to expired airtime contracts and new cost structures.
- Expense Reduction: Operating expenses dropped 72% year-over-year in Q2. This improvement was primarily due to the absence of a $9.8 million impairment loss recorded in Q2 2024 (related to goodwill and intangible assets) and reduced stock-based compensation.
- Cash Flow: Net cash used in operating activities increased to $3.1 million for the six months ended June 30, 2025, compared to $0.4 million in the prior year period, largely due to decreased cash receipts from Healthcare operations.
Outlook, Risks, and Management Commentary
- Liquidity: Management states that existing cash resources ($16.6 million) are sufficient to support operations for the next 12 months. The company is implementing cost reduction measures and exploring strategic alternatives.
- Tariff Risks: The filing highlights significant risk from U.S. and Chinese tariffs. While the first half of 2025 saw no material impact, tariffs introduced in Q2 2025 affect costs for goods imported into the U.S. Additionally, retaliatory Chinese tariffs have paused the launch of the "Florida Sunshine" vitamin brand in China.
- Legal Proceedings:
- Weisberg Class Action: A putative class action filed by former RXMD CEO Alan Jay Weisberg alleges breach of fiduciary duty regarding the RXMD merger. The company plans to vigorously defend and has filed a motion to dismiss.
- Employment Litigation: A former employee filed an EEOC claim against Pharmco LLC; the outcome is currently undeterminable.
- Internal Controls: The company previously identified a material weakness regarding inventory valuation. Management reports this has been remediated as of June 30, 2025, through new policies and senior management oversight.
- Corporate Changes: Two directors resigned in August 2025 for personal reasons. Lauren Sturges Fernandez, wife of the late CEO, was elected to the Board to fill a vacancy.
Investor Verification Checklist
- 340B Contract Stability: Verify the reasons for the 68% drop in 340B revenue (clients opening in-house pharmacies or leaving the program) and assess the sustainability of remaining contracts.
- Healthcare Volume Trends: Confirm the trajectory of prescription fill volumes, which dropped from 133,000 in Q2 2024 to 91,000 in Q2 2025, and the impact of insurance network changes.
- Tariff Exposure: Assess the specific impact of new tariffs on the e-Commerce segment's cost of goods sold and the viability of the paused China expansion plans.
- Legal Contingencies: Monitor the status of the Weisberg class action lawsuit and the EEOC claim for potential financial accruals.
- Inventory Valuation: Review the new internal controls for inventory net realizable value (NRV) to ensure the material weakness is fully resolved and no further write-downs are imminent.